Treatment outcomes after highly active antiretroviral therapy: a meta-analysis of randomised controlled trials

被引:19
作者
Enanoria, WTA
Ng, C
Saha, SR
Colford, JM
机构
[1] Univ Calif Berkeley, Dept Epidemiol, Berkeley, CA 94720 USA
[2] Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis, Berkeley, CA 94720 USA
关键词
D O I
10.1016/S1473-3099(04)01057-6
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
This systematic review summarises the evidence for treatment efficacy and tolerability of highly active antiretroviral therapies containing two nucleoside reverse transcriptase inhibitors (NRTI) with a protease inhibitor (PI), compared with two NRTIs alone for the treatment of HIV-1 infection in randomised controlled trials. Three electronic databases (Medline, Embase, and the Cochrane Library) were searched up to December 2003. 16 randomised controlled trials met the inclusion criteria and were included in the analysis from 328 articles screened. The pooled analysis indicated that treatment with two NRTIs with a PI is more effective in achieving viral suppression than two NRTIs alone (relative risk [RR] 3.44, 95% confidence interval [CI] 2.43-4.87). However, the RR for discontinuation of treatment due to adverse events of treatment with two NRTIs with a PI compared with two NRTIs alone was 1.81 (95% Cl 1.17-2.79). The benefits of treatment with two NRTIs and a PI are substantial among those who can tolerate the regimen in comparison with treatment with two NRTIs alone.
引用
收藏
页码:414 / 425
页数:12
相关论文
共 65 条
[1]  
*AIDS CLIN TRIAL G, 1996, TABL GRAD SEV AD ADV
[2]  
Ammassari A, 2001, J ACQ IMMUN DEF SYND, V28, P445, DOI 10.1097/00042560-200112150-00006
[3]  
[Anonymous], 1998, MMWR Recomm Rep, V47, P1
[4]  
[Anonymous], SYSTEMATIC REV HLTH
[5]   Psychosocial aspects of antiretroviral medication use among HIV patients [J].
Aversa, SL ;
Kimberlin, C .
PATIENT EDUCATION AND COUNSELING, 1996, 29 (02) :207-219
[6]  
Bassetti S, 1999, J ACQ IMMUN DEF SYND, V21, P114
[7]   Management of the adverse effects of antiretroviral therapy and medication adherence [J].
Blake, M ;
Sherer, R .
CLINICAL INFECTIOUS DISEASES, 2000, 30 :S96-S116
[8]   Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease [J].
Cameron, DW ;
Heath-Chiozzi, M ;
Danner, S ;
Cohen, C ;
Kravcik, S ;
Maurath, C ;
Sun, E ;
Henry, D ;
Rode, R ;
Potthoff, A ;
Leonard, J .
LANCET, 1998, 351 (9102) :543-549
[9]   Improvement of the study, analysis, and reporting of adverse events associated with antiretroviral therapy [J].
Carr, A .
LANCET, 2002, 360 (9326) :81-85
[10]   Adverse effects of antiretroviral therapy [J].
Carr, A ;
Cooper, DA .
LANCET, 2000, 356 (9239) :1423-1430